Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best stocks to buy with over 50% upside potential. Canaccord Genuity analyst Edward Nash maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT) on October 21, setting a 140pricetarget.WhyCorceptTherapeuticsIncorporated(CORT)CrashedOnMondaySimilarly,H.C.WainwrightanalystSwayampakulaRamakanthalsomaintainedaBuyratingonCorceptTherapeuticsIncorporated(NASDAQ:CORT)onOctober20,andseta145 price ta ...